Biogen has decided to minimize the commercialization infrastructure of the Alzheimer's drug Aduhelm and focus on developing subsequent drugs. In fact, it is unclear whether Aduhelm, which is in the process of eviction, will be introduced in Korea.

Biogen announced in its first-quarter earnings announcement on the 3rd (local time) that CEO Michel Vounatsos will resign due to responsibility for Aduhelm. CEO Michel Vounatsos will retire as soon as a successor is decided. At the same time, what attracts attention is the announcement that it will drastically reduce Aduhelm's commercial infrastructure.

Biogen said it minimizes all infrastructure for Aduhelm's commercialization. In the previousl